Form 4: Beta Bionics Director Sells Shares Under 10b5-1 Plan

Beta Bionics Director Maria Palasis sold 1,406 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Maria Palasis, a Director of Beta Bionics, Inc. (BBNX), reported transactions involving the sale of common stock.
• On December 1, 2025, Palasis sold 906 shares of common stock at a weighted average price of $29.3269 per share, with prices ranging from $28.75 to $29.63.
• On the same date, an additional 500 shares of common stock were sold at a weighted average price of $29.9640 per share, with prices ranging from $29.80 to $30.23.
• These sales, totaling 1,406 shares, were executed pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.
• Following these transactions, Maria Palasis beneficially owns 8,435 shares of Beta Bionics, Inc. common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling shares, which can sometimes be perceived unfavorably by the market. However, this is mitigated by the fact that the sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned rather than reactive decision.

Negatives

• A director selling shares, even under a pre-arranged plan, can be interpreted by the market as a signal of reduced confidence or a desire for diversification, potentially leading to negative sentiment.

Risks

• Potential negative market perception due to insider selling, which could exert downward pressure on the company's stock price.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially influencing their investment decisions or market sentiment towards the stock.

Key Dates

Recommendation

A director's sale of shares, even under a pre-arranged 10b5-1 plan, warrants a 'hold' recommendation as it can signal a lack of conviction or a need for liquidity. While not inherently negative due to the pre-planned nature, it does not provide a strong positive catalyst for investment and suggests a cautious stance.

Keywords

Beta Bionics, BBNX, Form 4, Insider Trading, Stock Sale, Director, Maria Palasis, 10b5-1 Plan